{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:48:24Z","timestamp":1764510504107,"version":"3.37.3"},"reference-count":48,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,12,28]],"date-time":"2014-12-28T00:00:00Z","timestamp":1419724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Salvage therapy followed by high\u2010dose therapy (<jats:styled-content style=\"fixed-case\">HDT<\/jats:styled-content>) remains a mainstay for patients with relapsed lymphoma, however no optimal regimen has been defined. Here we report on the results of R\u2010Dexa<jats:styled-content style=\"fixed-case\">BEAM<\/jats:styled-content> (rituximab, dexamethasone, carmustine, etoposide, cytarabine, melphalan) followed by <jats:styled-content style=\"fixed-case\">HDT<\/jats:styled-content>. Patients aged 18\u201365\u00a0years, Eastern Cooperative Oncology Group performance score 0\u20132, with relapsed\/refractory B\u2010cell non\u2010Hodgkin lymphoma (<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>) were eligible. R\u2010Dexa\u2010<jats:styled-content style=\"fixed-case\">BEAM<\/jats:styled-content> was given for two cycles followed by stem cell mobilization and <jats:styled-content style=\"fixed-case\">HDT<\/jats:styled-content>. Primary endpoint of the trial was progression\u2010free\u2010survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>). One hundred and three patients were included: aggressive <jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">aNHL<\/jats:styled-content>): diffuse large B\u2010cell lymphoma 55, mantle cell lymphoma 7, follicular lymphoma <jats:styled-content style=\"fixed-case\">(FL<\/jats:styled-content>) grade 3: 5, indolent Lymphoma (<jats:styled-content style=\"fixed-case\">iNHL<\/jats:styled-content>): <jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content> grade 1\u20132: 29, marginal zone lymphoma 6, Immunocytoma 1. The overall response rate after salvage therapy was 62% for <jats:styled-content style=\"fixed-case\">aNHL<\/jats:styled-content> and 78% for <jats:styled-content style=\"fixed-case\">iNHL<\/jats:styled-content> patients. 66% of patients with <jats:styled-content style=\"fixed-case\">aNHL<\/jats:styled-content> and 86% with <jats:styled-content style=\"fixed-case\">iNHL<\/jats:styled-content> underwent <jats:styled-content style=\"fixed-case\">HDT<\/jats:styled-content>. Treatment\u2010related mortality for <jats:styled-content style=\"fixed-case\">HDT<\/jats:styled-content> was 1\u00b73%. For <jats:styled-content style=\"fixed-case\">aNHL<\/jats:styled-content> patients, the median <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> was 0\u00b783\u00a0years with 44% alive at the median follow\u2010up of 7\u00b73\u00a0years. Corresponding figures for <jats:styled-content style=\"fixed-case\">iNHL<\/jats:styled-content> were: median <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> 3\u00b77\u00a0years and 72% alive after 8\u00a0years. The combination of rituximab with Dexa<jats:styled-content style=\"fixed-case\">BEAM<\/jats:styled-content> followed by <jats:styled-content style=\"fixed-case\">HDT<\/jats:styled-content> resulted in high response rates and sustained remissions in responders. R\u2010Dexa<jats:styled-content style=\"fixed-case\">BEAM<\/jats:styled-content> followed by <jats:styled-content style=\"fixed-case\">HDT<\/jats:styled-content> can be considered a valid salvage option for <jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.13234","type":"journal-article","created":{"date-parts":[[2014,12,29]],"date-time":"2014-12-29T04:45:49Z","timestamp":1419828349000},"page":"824-834","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Rituximab combined with Dexa<scp>BEAM<\/scp> followed by high dose therapy as salvage therapy in patients with relapsed or refractory B\u2010cell lymphoma: mature results of a phase <scp>II<\/scp> multicentre study"],"prefix":"10.1111","volume":"168","author":[{"given":"Sebastian","family":"Kirschey","sequence":"first","affiliation":[{"name":"Department of Haematology Oncology and Pneumology University Medical School of the Johannes Gutenberg University Mainz Mainz Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Flohr","sequence":"additional","affiliation":[{"name":"Onkologische Gemeinschaftspraxis Mainz Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans H.","family":"Wolf","sequence":"additional","affiliation":[{"name":"Martin\u2010Luther\u2010University Halle\u2010Wittenberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Frickhofen","sequence":"additional","affiliation":[{"name":"HSK Dr.\u2010Horst\u2010Schmidt\u2010Kliniken Wiesbaden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Gramatzki","sequence":"additional","affiliation":[{"name":"University of Erlangen\u2010N\u00fcrnberg N\u00fcrnberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Link","sequence":"additional","affiliation":[{"name":"Westpfalz\u2010Klinikum Kaiserlautern Kaiserslautern Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadezda","family":"Basara","sequence":"additional","affiliation":[{"name":"Malteser Krankenhaus St. Franziskus\u2010Hospital Flensburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norma","family":"Peter","sequence":"additional","affiliation":[{"name":"Carl\u2010Thiem\u2010Klinikum Cottbus Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf G.","family":"Meyer","sequence":"additional","affiliation":[{"name":"Department of Haematology Oncology and Pneumology University Medical School of the Johannes Gutenberg University Mainz Mainz Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Schmitz","sequence":"additional","affiliation":[{"name":"Asklepios\u2010Klinik St. Georg Hamburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eckhart","family":"Weidmann","sequence":"additional","affiliation":[{"name":"Klinikum Nordwest Frankfurt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Banat","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Gesundheitszentrum Wetterau gGmbH Bad Nauheim Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Schulz","sequence":"additional","affiliation":[{"name":"Department of Haematology Oncology and Pneumology University Medical School of the Johannes Gutenberg University Mainz Mainz Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Kolbe","sequence":"additional","affiliation":[{"name":"Department of Haematology Oncology and Pneumology University Medical School of the Johannes Gutenberg University Mainz Mainz Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guenter","family":"Derigs","sequence":"additional","affiliation":[{"name":"St\u00e4dtisches Klinikum Frankfurt\u2010H\u00f6chst Frankfurt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Theobald","sequence":"additional","affiliation":[{"name":"Department of Haematology Oncology and Pneumology University Medical School of the Johannes Gutenberg University Mainz Mainz Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Hess","sequence":"additional","affiliation":[{"name":"Department of Haematology Oncology and Pneumology University Medical School of the Johannes Gutenberg University Mainz Mainz Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,12,28]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"3562","article-title":"The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group","volume":"92","author":"Blay J.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.10.1615"},{"key":"e_1_2_9_4_1","first-page":"115","article-title":"Stem cell function and engraftment is not affected by ;in vivo purging' with rituximab for autologous stem cell treatment for patients with low\u2010grade non\u2010Hodgkin's lymphoma","volume":"26","author":"Buckstein R.","year":"1999","journal-title":"Seminars in Oncology"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700913"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20587"},{"key":"e_1_2_9_9_1","article-title":"Gemcitabine, Dexamethasone, Cisplatin (GDP) compared with Dexamethasone, Cytarabine, Cisplatin (DHAP) salvage chemotherapy prior to autologus tem cell transplantation for relapsed and refractroy aggressive lymphoma: final result of the pahse III NCIC CTGH study Ly12","volume":"31","author":"Crump M.","year":"2013","journal-title":"Hematological Oncology"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703515"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333"},{"key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.V110.11.22.22","article-title":"90Yttrium ibritumomab tiuxetan (Zevalin) combined with BEAM (Z \u2010BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory follicular lymphoma GELA phase II study","volume":"110","author":"Gisselbrecht C.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.9416"},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1200\/jco.2012.30.15_suppl.8004","article-title":"High\u2010dose chemotherapy followed by allogeneic stem cell transplantation in high\u2010risk relapsed and refractory aggressive non\u2010Hodgkin lymphoma: results of a prospective study of the German high\u2010grade non\u2010Hodgkin lymphoma study group","volume":"30","author":"Glass B.","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0622"},{"key":"e_1_2_9_18_1","doi-asserted-by":"crossref","first-page":"6543","DOI":"10.1200\/jco.2012.30.15_suppl.6543","article-title":"Minimum tolerable interval of 90yttrium ibritumomab\u2010tiuxetan to autologous stem cell transplantation after high\u2010dose chemotherapy with carmustin, etoposide, cytarabine, and melphalan for relapsed or refractory aggressive B\u2010cell non\u2010Hodgkin lymphoma","volume":"30","author":"Hasenkamp J.","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.091538"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-006-0157-6"},{"key":"e_1_2_9_21_1","first-page":"352a","article-title":"Combined immunochemotherpy (R\u2010CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma. Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)","volume":"102","author":"Hiddemann W.","year":"2003","journal-title":"Blood"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3911"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200920"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.3.864"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.8.2457.2457"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.10.3266"},{"key":"e_1_2_9_27_1","first-page":"194","article-title":"DHAP treatment: results of 18 patients with refractory or recurrent non Hodgkin's lymphoma","volume":"75","author":"Martelli M.","year":"1990","journal-title":"Haematologica"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-472027"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802094229"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404850"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701624"},{"key":"e_1_2_9_32_1","first-page":"85","article-title":"DHAP regimen plus G\u2010CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma","volume":"16","author":"Olivieri A.","year":"1995","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.7.1587.1587"},{"key":"e_1_2_9_34_1","first-page":"1540","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy\u2010sensitive non\u2010Hodgkin's lymphoma. N.Engl","volume":"333","author":"Philip T.","year":"1995","journal-title":"Journal of Medicine"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92225-3"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.83"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1177"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.8327"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.7.2579.2579"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.5358"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705919"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706113162402"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.4204"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V71.1.117.117"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-108415"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.138"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.9453"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02084.x"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13234","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T15:34:05Z","timestamp":1696347245000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,28]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1111\/bjh.13234"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13234","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2014,12,28]]},"assertion":[{"value":"2014-07-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-10-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-12-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}